Acadia Healthcare Q2 Earnings Call Highlights
Acute care: Revenue was $495 million, flat year over year but up 6% after normalizing for supplemental payments. Management cited strong volumes and admissions at existing acute facilities as well as newer joint-venture and de novo locations. Specialty care: Revenue was $134 million, up 4% sequentially from the first quarter. The business experienced the full-quarter impact of the New York Medicaid decision.
How this was made
The 30-second read
Why it matters
Traders can reprice ACHC based on the updated 2026 targets, the revised capex plan, and the stated expectation for positive free cash flow in the second half. The supplemental-payment regulatory review in Florida and Ohio is a key optionality driver, while Q3 start-up losses are a near-term headwind.
Market read
Updated 2026 guidance plus capex discipline and cash generation are the primary repricing inputs, with regulatory-review upside and Q3 start-up losses shaping the near-term risk/reward.
What to watch
The article notes the New York Medicaid decision impacted specialty care and that liability reserve adjustments include prior-year case movement, which could complicate quarter-to-quarter comparability.
Background
Acadia Healthcare reported Q2 operating metrics and used the earnings call to update 2026 revenue, EBITDA, EPS, and cash-flow outlook, alongside facility expansion and ramp assumptions.
Ticker impact
Acadia updated 2026 guidance and revised capex to $235M-$255M, citing cash flow, debt repayment, and supplemental-payment regulatory review.
Likely positive bias if investors view the capex discipline and cash generation as de-risking 2026 EBITDA, partially offset by higher third-quarter start-up losses.
The article provides specific updated full-year targets (revenue, EBITDA, EPS, operating cash flow) plus a capex range and cash/debt metrics, which are direct inputs to valuation and positioning. It also flags regulatory-review upside for incremental EBITDA, but with uncertainty and timing.
Market effects
Behavioral healthcare operators may see read-through on how quickly new facilities ramp and how supplemental-payment programs affect earnings sensitivity.
Florida and Ohio regulatory review is highlighted as a potential earnings swing factor for providers with exposure to those states.
Limited, as the disclosures are company-specific and US Medicaid/supplemental-payment related.
Counterpoint
The guidance upside depends on supplemental-payment program expansion that is under regulatory review, while start-up facility losses may rise in Q3.
Key entities
- companyAcadia Healthcare Company, Inc.
Behavioral healthcare provider issuing Q2 call highlights and updated 2026 guidance, including capex and cash-flow expectations.
- executiveDebbie Osteen
CEO cited facility ramp progress, occupancy, and incremental EBITDA targets from newer facilities.
- executiveDuckworth
Management speaker discussing start-up losses, labor costs, reserves, and the supplemental-payment regulatory review outlook.
